Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational lung cancer research Chuang, J. C., Neal, J. W. 2015; 4 (5): 639-641
View details for DOI 10.3978/j.issn.2218-6751.2015.03.06
View details for PubMedID 26629437
View details for PubMedCentralID PMC4630528